Business Responsibility and Sustainability Report
Section A: General Disclosures
I.	
Details of the listed entity
1.	
Corporate Identity Number (CIN) of the Listed Entity
L21002MH2023PLC402652
2.	
Name of the Listed Entity
Sanofi Consumer Healthcare India Limited
3.	
Year of incorporation
May 10, 2023
4.	
Registered office address
Unit 1104, 11th Floor, Godrej Two, Pirojshanagar, 
Eastern Express Highway, Vikhroli East, Mumbai, 
Maharashtra, 400079
5.	
Corporate address
Unit 1104, 11th Floor, Godrej Two, Pirojshanagar,
Eastern Express Highway, Vikhroli East, Mumbai,
Maharashtra, 400079
6.	
E-mail
igrc.schil@sanofi.com
7.	
Telephone
022-4528 8855
8.	
Website
https://www.sanofi.com/en/india
9.	
Financial year for which reporting is being done
January 2024 to December 2024 
The Company was incorporated in 2023 as part of Sanofi’s 
global strategy to establish a standalone Consumer 
Healthcare business. This report comprises qualitiative 
and quantitative performance during CY 2024. Pursuant 
to this strategy, the Consumer Healthcare business was 
demerged from Sanofi India Limited into the Company 
through a Scheme of Arrangement, which became effective 
on June 1, 2024. Accordingly, the Business Responsibility & 
Sustainability Report presents data for the period from June 
1, 2024, to December 31, 2024. This report comprises 
qualitative and quantitative performance during CY 2024.
10.	 Name of the Stock Exchange(s) where shares are listed
BSE Limited & National Stock Exchange of India Limited
11.	 Paid-up Capital
230,306,220
12.	 Name and contact details (telephone, email address) 
of the person who may be contacted in case of any 
queries on the BRSR report
Himanshu Bakshi, Managing Director
Tel. No.: (22) 45288855 
E-mail: igrc.schil@sanofi.com
13.	 Reporting boundary - Are the disclosures under this 
report made on a standalone basis (i.e. only for the 
entity) or on a consolidated basis (i.e. for the entity  
and all the entities which form a part of its 
consolidated financial statements, taken together).
The disclosures made in this report are on a standalone 
basis.
II.	
Product/Services
14. Details of business activities (accounting for 90% of the turnover):
Sr. 
No.
Description of Main Activity
Description of Business Activity
% of Turnover of the entity
1.
Manufacture and sale of 
pharmaceutical products
Drugs and Pharmaceuticals
100%
15. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover):
Sr. 
No.
Product/Service
NIC Code
% of total Turnover contributed
1.
Drugs and Pharmaceuticals
21002
100%
Annual Report 2024
01
III.
Operations
16. Number of locations where plants and/or operations/offices of the entity are situated:
Location
Number of Plants
Number of Offices
Total
National
0
1
1
International
0
0
0
17. Markets served by the entity
a. 
Number of locations
Location
Number
National (No. of States)
29
International (No. of Countries)
2
b. 
What is the contribution of exports as a percentage of the total turnover of the entity?
The contribution of exports as a percentage of the total turnover is 9%.
c. 
A brief on types of customers
	Sanofi Consumer Healthcare India Limited serves a diverse customer base, including stockists, healthcare
professionals, and government institutions. We ensure seamless product supply to these stakeholders while actively
engaging with them to enhance distribution efficiency and product utilization. Our commitment to reliability, quality,
and customer-centricity strengthens collaborative relationships, driving excellence in healthcare delivery and public
health advancement.
IV.
Employees
18. Details as at the end of financial year:
a. 
Employees and workers (including differently abled):
Sr. 
No. Particulars
Total (A)
Male
Female
No.(B)
%(B/A)
No.(C)
%(C/A)
EMPLOYEES
1.
Permanent(D)
493
401
81%
92
19%
2.
Other than Permanent (E)
0
0
0%
0
0%
3.
Total employees (D+E)
493
401
81%
92
19%
WORKERS
4.
Permanent(F)
90
87
97%
3
3%
5.
Other than Permanent (G)
0
0
0%
0
0%
6.
Total workers (F+G)
90
87
97%
3
3%
b. 
Differently abled Employees and workers:
Sr. 
No. Particulars
Total (A)
Male
Female
No.(B)
%(B/A)
No.(C)
%(C/A)
DIFFERENTLY ABLED EMPLOYEES
1.
Permanent(D)
0
0
0%
0
0%
2.
Other than Permanent (E)
0
0
0%
0
0%
3.
Total differently abled employees 
(D+E)
0
0
0%
0
0%
DIFFERENTLY ABLED WORKERS
4.
Permanent(F)
0
0
0%
0
0%
5.
Other than Permanent (G)
0
0
0%
0
0%
6.
Total differently abled workers (F+G)
0
0
0%
0
0%
02
Sanofi Consumer Healthcare India Limited
19. Participation/Inclusion/Representation of women:
Total (A)
No. and percentage of Females
No.(B)
%(B/A)
Board of Directors
7
3
43%
Key Management Personnel*
3*
0
0%
 
* 2 out of 3 KMPs are also Board Members.
20. Turnover rate for permanent employees and workers:
CY 2024
CY 2023*
CY 2022*
Male
Female
Total
Male
Female
Total
Male
Female
Total
Permanent 
Employees
3.99
5.49
5.37
NA
NA
NA
NA
NA
NA
Permanent Workers
0%
0%
0%
NA
NA
NA
NA
NA
NA
 
*For CY 2022 and 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 
2023 and demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, 
therefore, covers the period from June 1, 2024, to December 31, 2024.
V. 
Holding, Subsidiary and Associate companies (including joint ventures)
21.  Names of holding/subsidiary/associate companies/joint ventures
Sr. 
No.
Name of the holding/
subsidiary/associate 
companies/joint 
ventures (A)
Indicate whether  
holding/subsidiary/
associate/joint venture
% of shares held 
of the company
Does the entity indicated at 
column A, participate in the 
Business Responsibility initiatives 
of the listed entity? (Yes/No)
1.
Opella Healthcare 
Participations B.V.
Holding Company
60.40%
No
VI. CSR Details
22. (i) 
Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes
 
(ii) Turnover (in `): 7,245.46 Million
	
(iii) Net worth (in `): 2,729.09 Million
VII. Transparency and Disclosures Compliances
23.  Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible 
Business Conduct:
Stakeholder 
group from 
whom 
complaint is 
received
Grievance Redressal 
Mechanism in Place  
(Yes/No) (If yes, then 
provide web-link for 
grievance redress policy)
CY 2024
CY 2023*
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution at 
close of the 
year
Remarks
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution at 
close of the 
year
Remarks
Communities
Yes, we have a mechanism in 
place to receive and redress 
stakeholder complaints.  
(www.sanofi.in)
0
0
-
NA
NA
NA
Investors 
(other than 
shareholders)
Yes, we have a mechanism in 
place to receive and redress 
stakeholder complaints. 
0
0
_
NA
NA
NA
Shareholders
4
0
NA
NA
NA
NA
Annual Report 2024
03
Stakeholder 
group from 
whom 
complaint is 
received
Grievance Redressal 
Mechanism in Place  
(Yes/No) (If yes, then 
provide web-link for 
grievance redress policy)
CY 2024
CY 2023*
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution at 
close of the 
year
Remarks
Number of 
complaints 
filed during 
the year
Number of 
complaints 
pending 
resolution at 
close of the 
year
Remarks
Employees and 
workers
Yes, we have a mechanism in 
place to receive and redress 
stakeholder complaints.
(www.sanofi.in)
02
01
#
NA
NA
NA
Customers
Yes, we have a mechanism in 
place to receive and redress 
stakeholder complaints. 
(www.sanofi.in)
138
0
-
NA
NA
NA
Value Chain 
Partners
Yes, we have a mechanism in 
place to receive and redress 
stakeholder complaints.
0
0
NA
NA
NA
NA
* For the year 2023, data are not applicable as the entity became independent on June 1, 2024, following its 
incorporation in 2023 and demerger from Sanofi India Limited via a Scheme of Arrangement. The Business 
Responsibility & Sustainability Report, therefore, covers the period from June 1, 2024, to December 31, 2024.
# The complaint currently pending is undergoing a formal investigation.
24. Overview of the entity’s material responsible business conduct issues. 
	
Please indicate material responsible business conduct and sustainability issues pertaining to environmental and social 
matters that present a risk or an opportunity to your business, rationale for identifying the same, approach to adapt 
or mitig ate the risk along-with its financial implications, as per the following format:
Sr. 
No.
Material issue 
identified
Indicate 
whether 
risk or 
opportunity 
(R/O)
Rationale for 
identifying the risk/
opportunity
In case of risk, 
approach to adapt or 
mitigate
Financial implications of 
the risk or opportunity 
(Indicate positive or negative 
implications)
1.
Ethical 
Business
Practices
Risk
Running our daily 
activities in an ethical 
way (e.g., ethical 
marketing, lobbying, 
anti-bribery measures 
etc.)
i.	
Development of 
Code of Conduct
ii.	 Development of 
policies, programs 
and mechanism for 
avoiding unethical 
practices
Negative: Any instances of 
unethical practices have 
the risk of tarnishing our 
reputation and attracting fine/
penalty/lawsuits which can in 
turn affect business continuity
2.
Safe and 
qualitative 
treatments for 
patients and 
clinical trial 
participants
Risk and 
Opportunity
Ensuring the safety 
of our patients 
and clinical trial 
participants by 
providing high 
quality, safe and 
effective medicines 
and recording and 
communicating on any 
safety or quality issues
We believe that it is our 
responsibility to provide 
our consumers with safe 
products that positively 
impact health outcomes 
for society. Our Quality 
and Pharmacovigilance 
teams proactively track 
regulatory and non-
regulatory complaints 
and grievances 
and works towards 
redressing them in a 
timely and effective 
manner.
Negative: Any health and 
safety incident can lead to 
decreased trust amongst 
our customers and adversely 
impacted the demand of 
products. Moreover, instances 
of non-compliance with 
product marketing and 
labeling can lead to legal 
implications and reputation 
damage. 
04
Sanofi Consumer Healthcare India Limited
Sr. 
No.
Material issue 
identified
Indicate 
whether 
risk or 
opportunity 
(R/O)
Rationale for 
identifying the risk/
opportunity
In case of risk, 
approach to adapt or 
mitigate
Financial implications of 
the risk or opportunity 
(Indicate positive or negative 
implications)
3.
Employee 
health, safety, 
wellbeing 
and working 
condition
Risk and 
Opportunity
Providing a safe 
& healthy (Both 
physical and mental) 
work environment 
for all employees 
and ensuring fair 
employment practices 
(e.g., upholding labor 
rights, freedom of 
association)
i.	
Implementation 
of a Company-
wide robust HSE 
management system 
ii.	 Ensuring periodic 
internal and external 
audits
iii.	 Training all 
employees and 
workers on safe 
working practices
iv.	 Investigation of each 
reported case and 
taking corrective 
actions to avoid 
reoccurrence
Negative: The nature of 
operations exposes Sanofi 
Consumer Healthcare India's 
employees and contractors 
to a wide range of safety 
risks due to complexity of 
operational requirements.  
4.
Responsible 
governance 
practices
Opportunity Governing our business 
in a responsible 
way by considering 
ESG factors in our 
operational and 
strategic business 
decisions (e.g., 
remuneration, 
providing transparency 
to stakeholders, capital 
allocation etc.)
_
Positive: Leadership oversight 
on the ESG strategy, action 
plan and performance promote 
the Company’s positive 
impact on environment and 
community. It also enables 
us to further embed robust 
ESG mechanisms across our 
business operations.
5.
Health system 
strengthening
Opportunity Contributing to 
improving healthcare 
infrastructure, 
healthcare access, and 
health education (e.g. 
health literacy, disease 
prevention awareness)
_
Positive: We strive to improve 
the healthcare system across 
our markets and understand 
the importance of being a 
responsible organization. 
We endeavour to solve the 
problems of lack of product 
availability and pricing and 
work towards business growth 
in the long term.
Annual Report 2024
05
Section B: Management And Process Disclosures
The National Guidelines for Responsible Business Conduct (NGRBC) as prescribed by the Ministry of Corporate Affairs 
advocates nine principles referred as P1-P9 as given below:
Principle 1:	 Businesses should conduct and govern themselves with integrity in a manner that is ethical, transparent and 
accountable.
Principle 2:	 Businesses should provide goods and services in a manner that is sustainable and safe.
Principle 3:	 Businesses should respect and promote the well-being of all employees, including those in their value chains.
Principle 4:	 Businesses should respect the interests of and be responsive towards all its stakeholders.
Principle 5:	 Businesses should respect and promote human rights.
Principle 6:	 Businesses should respect, protect, and make efforts to restore the environment.
Principle 7:	 Businesses when engaging in influencing public and regulatory policy, should do so in a manner that is 
responsible and transparent
Principle 8:	 Businesses should promote inclusive growth and equitable development
Principle 9:	 Businesses should engage with and provide value to their consumers in a responsible manner.
This section is aimed at helping businesses demonstrate the structures, policies and processes put in place towards 
adopting the NGRBC Principles and Core Elements.
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
Policy and management processes
1. a. Whether your entity’s policy/policies cover 
each principle and its core elements of the 
NGRBCs. (Yes/No)
Y
Y
Y
Y
Y
Y
Y
Y
Y
 
b. Has the policy been approved by the Board? 
(Yes/No)
Y
Y
Y
Y
Y
Y
Y
Y
Y
 
c. Web Link of the Policies, if available.
Policies are uploaded on the website of the Company at  
www.sanofi.in and on the Company’s intranet portal
2. Whether the entity has translated the policy into 
procedures. (Yes/No)
Y
Y
Y
Y
Y
Y
Y
Y
Y
3.  Do the enlisted policies extend to your value 
chain partners?
Y
Y
Y
Y
Y
Y
Y
Y
Y
4.  Name of the national and international codes/
certifications/labels/standards (e.g. Forest 
Stewardship Council, Fairtrade, Rainforest 
Alliance, Trustea) standards (e.g. SA 8000, 
OHSAS, ISO, BIS) adopted by your entity and 
mapped to each principle.
Policies have been formulated considering pertinent national 
standards and various other statutes. Additionally, these policies 
have been aligned with various global standards, including those 
established by the United Nations, the International Labour 
Organization, and various ISO standards. Sanofi is committed to the 
principles of the UN Global Compact and has signed a pact with 
the United Nations Decade of Action for Road Safety. Moreover, 
Sanofi has joined the Alliance for Water Stewardship (A4WS), a 
global network of public, private, and civil society organizations 
actively engaged in effective water stewardship initiatives.
5.  Specific commitments, goals and targets set by 
the entity with defined timelines, if any.
The Company is in the process of setting targets.
6. Performance of the entity against the specific 
commitments, goals and targets along-with 
reasons in case the same are not met.
Not Applicable - Since this is the first year of the reporting for the 
entity since its inception in June 2023, performamce mapping 
can only be done once the targets are set.
06
Sanofi Consumer Healthcare India Limited
Disclosure Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
Governance, leadership and oversight
7. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, 
targets and achievements (listed entity has flexibility regarding the placement of this disclosure)
	
At Sanofi, we are committed to fostering a nurturing and inclusive workplace that embraces gender diversity, upholds 
non-discrimination policies, and promotes work-life balance. The wellbeing and safety of our employees remain a 
top priority. We strive to deliver high-quality products and services to our customers with integrity and responsibility, 
guided by strong governance practices and a deep respect for the environment and society. Our robust business 
model—powered by emerging technologies, automation, brand equity, and a customer-centric mindset—underpins 
our strong economic performance. As we chase the miracles of science to improve lives, we are accelerating our ESG 
journey to embed sustainability at the core of our operations and shape a resilient, future-ready Sanofi.
8.  Details of the highest authority responsible for 
implementation and oversight of the Business 
Responsibility policy (ies).
Mr. Himanshu Bakshi, Managing Director.
9.  Does the entity have a specified Committee 
of the Board/Director responsible for decision 
making on sustainability related issues? (Yes/No). 
If yes, provide details.
Mr. Himanshu Bakshi
At Sanofi Consumer Healthcare India Limited, ESG matters 
are overseen by a dedicated Management-level Committee 
headed by the Managing Director. This Committee meets at 
regular intervals to evaluate progress on ESG initiatives, ensuring 
alignment with the company’s sustainability commitments and 
business objectives.
10. Details of review of NGRBCs by the Company:
Subject for review
Indicate whether review was undertaken 
by Director/Committee of the Board/
Any other Committee
Frequency (Annually/Half yearly/
Quarterly/Any other-please specify
P1
P2
P3
P4
P5
P6
P7
P8
P9
P1
P2
P3
P4
P5
P6
P7
P8
P9
Performance against 
above policies and follow 
up action
Y
Y
Y
Y
Y
Y
Y
Y
Y
Yes; The policies and performance undergo 
periodic review for Sanofi Consumer 
Healthcare India Limited.
Compliance with statutory 
requirements of relevance 
to the principles, and, 
rectification of any 
non-ompliances
Y
Y
Y
Y
Y
Y
Y
Y
Y
Our policies are periodically reviewed 
to ensure continued compliance with 
statutory requirements and regulatory 
standards.
 
Note: In line with the Company’s Code of Conduct, all Board level meetings and business meetings are led by the Managing Director 
for sustainability and business responsibility discussions on a continual basis. The Directors and Senior Management members 
affirm compliance with the Code of Conduct on an annual basis.
 
As a company incorporated in June 2023, we are pleased to present our first Business Responsibility and Sustainability Report 
(BRSR) as part of our Annual Report. From inception, we have embedded our commitment to responsible business practices into 
our governance structures. The Corporate Social Responsibility (CSR) Committee was constituted soon after incorporation and 
is responsible for formulating, implementing, and monitoring the Company’s CSR Policy under the guidance of the Board. The 
Committee includes the Managing Director as a member and is scheduled to meet at least twice a year to review the progress of 
CSR initiatives. Additionally, the Health, Safety and Environment (HSE) Committee has been established to regularly assess and 
guide the Company’s performance on key health, safety, and environmental parameters. The CSR Committee also approves the 
Annual CSR Report in line with the provisions of the Companies Act.
Annual Report 2024
07
11. Has the entity carried out independent assessment/evaluation of the working of its policies by an 
external agency? (Yes/No) If yes, provide the name of the agency.
P1
P2
P3
P4
P5
P6
P7
P8
P9
The majority of our policies are internal, with only a few falling under Global policies. Our Company adheres to these 
policies and conducts regular internal reviews, excluding external partners from the review process.
12. If answer to question (1) above is “No” i.e., not all Principles are covered by a policy, reasons to be 
stated:
Questions
P1
P2
P3
P4
P5
P6
P7
P8
P9
The entity does not consider the principles material to its 
business (Yes/No)
Not Applicable
The entity is not at a stage where it is in a position to 
formulate and implement the policies on specified 
principles (Yes/No)
The entity does not have the financial or/human and 
technical resources available for the task (Yes/No)
It is planned to be done in the next financial year (Yes/No)
Any other reason (please specify)
Section C: Principle Wise Performance Disclosure
Principle 1: Businesses should conduct and govern themselves with integrity, and in a manner that is 
Ethical, Transparent and Accountable.
Essential Indicators
1. 
Percentage coverage by training and awareness programmes on any of the principles during the financial year.
Segment
Total number 
of training and 
awareness 
programmes held
Topics/principles covered under the training 
and its impact
%age of persons in 
respective category 
covered by the 
awareness programmes
Board of 
Directors
8
During Board/Committee Meetings, directors 
receive regular presentations covering a range 
of topics essential to the Company’s operations. 
These include the Company’s strategy, business 
operations, market performance, organizational 
structure, product brands, finance, risk 
management, quarterly and annual financial 
results, human resources, technology, health, 
safety & environment, regulatory updates, 
whistleblower complaints, and the outlook. 
Furthermore, updates are provided on: 
	
Internal controls and compliance 
	
HR policies, compensation & benefits, talent 
management, and succession planning 
programs
	
Risk management strategy and framework
100%
Key 
Managerial 
Personnel
Employees 
other than 
BoD and 
KMPs
8
- 	 Speak up and UCPMP 
- 	 Insights Goal setting Global disciplinary 
Framework 
- 	 JDI Trainings 
- 	 Wellbeing and Career Development 
- 	 Data for diagnosis for managers 
- 	 Policy refreshers
100%
Workers
01
Policy refreshers
0%
08
Sanofi Consumer Healthcare India Limited
2. 
Details of fines/penalties/punishment/award/compounding fees/settlement amount paid in proceedings (by 
the entity or by directors/KMPs) with regulators/law enforcement agencies/judicial institutions, in the Financial 
year, in the following format (Note: the entity shall make disclosures on the basis of materiality as specified in 
Regulation 30 of SEBI (Listing Obligations and Disclosure Obligations) Regulations, 2015 and as disclosed on 
the entity’s website):
Monetary
NGRBC 
Principle
Name of the regulatory/
enforcement agencies/
judicial institutions
Amount  
(In `)
Brief of the 
Case
Has an appeal  
been preferred? 
(Yes/No)
Penalty/Fine
 Nil 
Settlement
Compounding fee
Non-Monetary
NGRBC 
Principle
Name of the regulatory/enforcement 
agencies/judicial institutions
Brief of the 
Case
Has an appeal been 
preferred? (Yes/No)
Imprisonment
 Nil 
Punishment
3. 
Of the instances disclosed in Question 2 above, details of the Appeal/Revision preferred in cases where 
monetary or non-monetary action has been appealed.
Case Details
Name of the regulatory/enforcement agencies/judicial institutions
Not Applicable
4. 
Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, 
provide a web-link to the policy.
	
We are completely aligned with Sanofi Global code of conduct to ensure highest level of governance and ethical 
considerations for all the employees with respect to anti corruption and anti bribery.
	
As a core component of the Global Code of Conduct, the Anti-Bribery Policy applies to all employees and extends 
to our business partners, including suppliers, service providers, agents, and channel partners, such as dealers and 
distributors.
5. 
Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law 
enforcement agency for the charges of bribery/corruption:
CY 2024
CY 2023
Directors
Nil
NA
KMPs
Nil
NA
Employees
Nil
NA
Workers
Nil
NA
6. 
Details of complaints with regards to conflict of interest:
CY 2024
CY 2023
Number
Remarks
Number
Remarks
Number of complaints received in relation to issues of 
Conflict of Interest of the Directors
Nil
NA
Nil
NA
Number of complaints received in relation to issues of 
Conflict of Interest of the KMPs
Nil
NA
Nil
NA
Annual Report 2024
09
7. 
Provide details of any corrective action taken or underway on issues related to fines/penalties/action taken by 
regulators/law enforcement agencies/judicial institutions, on cases of corruption and conflicts of interest.
	
Not Applicable
Leadership Indicators
1. 
Awareness programmes conducted for value chain partners on any of the principles during the financial year:
Total number of awareness 
programmes held
Topics/principles covered  
under the training
%age of value chain partners 
covered (by value of business done 
with such partners) under the 
awareness programmes
As an integral part of the 
onboarding process, Sanofi 
Consumer Healthcare India 
Limited ensures that 100% of its 
value chain partners are informed 
of the Supplier Code of Conduct, 
reinforcing our commitment to 
ethical and responsible business 
practices.
1.	 Counterfeit Medication 
2.	 Paramedic Educational Program 
for better patient care like nurses 
education program 
3.	 Cold chain management & Medicine 
4.	 Disease awareness program like 
Sepsis care meet, Pulmonary care 
meet, DVT awareness meet
Sanofi Consumer Healthcare India 
Limited ensures that all value chain 
partners receive comprehensive 
training on the Supplier Code of 
Conduct, reinforcing our commitment 
to ethical business practices and 
responsible sourcing.
2. 
Does the entity have processes in place to avoid/manage conflict of interests involving members of the Board? 
(Yes/No). If yes, provide details of the same.
	
Yes; Sanofi Consumer Healthcare India Limited is committed to upholding the highest standards of corporate 
governance through a well-defined Code of Conduct for the Board. This comprehensive framework establishes 
clear guidelines for addressing conflicts of interest, incorporating preventive measures and resolution mechanisms 
to ensure transparency, accountability, and ethical leadership.
	
During Board meetings, members proactively disclose any potential conflicts related to agenda items, fostering a 
culture of integrity and trust. A dedicated policy on related-party transactions further strengthens ethical decision-
making and reinforces the Company’s commitment to corporate responsibility. In instances of conflict, Board 
members recuse themselves from voting on the relevant matter to maintain objectivity and fairness in the decision-
making process.
	
For more details, refer to our Code of Business Conduct and Ethics for Directors and Senior Management, which 
underscores our dedication to strong governance principles. To explore our policies in-depth, visit our website: 
Code of Conduct and Policies
Principle 2: Business should provide goods and services in a manner that is sustainable and safe
Essential Indicators
1. 
Percentage of R&D and capital expenditure (capex) investments in specific technologies to improve the 
environmental and social impacts of product and processes to total R&D and capex investments made by the 
entity, respectively.
CY 2024
CY 2023
Details of improvements in environmental and social impacts
R&D
Nil
NA
NA
Capex
Nil
NA
NA
2. 
a. 
Does the entity have procedures in place for sustainable sourcing? (Yes/No)
	
	
No.
 
b. 
If yes, what percentage of inputs were sourced sustainably?
	
	
NA
10
Sanofi Consumer Healthcare India Limited
3. 
Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end 
of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.
	
At Sanofi Consumer Healthcare India Limited, we have established a robust waste management program to ensure 
the responsible handling and disposal of all waste materials. Our approach emphasizes systematic source segregation 
and strict adherence to regulatory requirements.
	
Non-hazardous materials such as plastic, paper, wood, metal, and glass are carefully collected and directed to 
authorized recyclers, while e-waste is managed through Pollution Control Board-approved facilities, ensuring 
environmentally compliant processing.
4. 
Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes/No). If yes, whether 
the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution 
Control Boards? If not, provide steps taken to address the same.
	
Sanofi Consumer Healthcare India Limited remains fully compliant with the Plastic Waste Management Rules, as 
periodically updated and mandated by regulatory authorities. In alignment with these guidelines, the Company 
collaborates with authorized waste management agencies to facilitate the collection of post-consumer plastic waste 
from municipal sources.
	
To ensure the responsible management of plastic waste and packaging generated by its products, Sanofi Consumer 
Healthcare has developed and implemented a structured collection plan in accordance with regulatory requirements. 
Furthermore, in fulfilment of its Extended Producer Responsibility (EPR) obligations, the Company has established 
robust mechanisms to support sustainable waste recovery and disposal practices.
Leadership Indicators
1. 
Has the entity conducted Life Cycle Perspective/Assessments (LCA) for any of its products (for manufacturing 
industry) or for its services (for service industry)? If yes, provide details in the following format?
NIC 
Code
Name of 
Product/
Service
% of total 
Turnover 
contributed
Boundary for which the 
Life Cycle Perspective/
Assessment was 
conducted
Whether conducted 
by independent 
external agency 
(Yes/No)
Results communicated 
in public domain 
(Yes/No) If yes, provide 
the web-link.
Nil; as LCA was not conducted in the CY 2024.
2. 
If there are any significant social or environmental concerns and/or risks arising from production or disposal 
of your products/services, as identified in the Life Cycle Perspective/Assessments (LCA) or through any other 
means, briefly describe the same along-with action taken to mitigate the same.
Name of Product/Service
Description of the risk/concern
Action Taken
Nil; as LCA was not conducted in the CY 2024.
3. 
Percentage of recycled or reused input material to total material (by value) used in production (for manufacturing 
industry) or providing services (for service industry).
Indicate input material
Recycled or re-used input  
material to total material
CY 2024
CY 2023
Not Applicable
Annual Report 2024
11
4. 
Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, 
and safely disposed, as per the following format:
CY 2024
CY 2023
Re-Used
Recycled
Safely 
Disposed
Re-Used
Recycled
Safely 
Disposed
Plastics (including packaging)
Nil
NA*
Nil
NA
NA
NA
E-waste
Nil
Nil
Nil
NA
NA
NA
Hazardous waste
Nil
Nil
Nil
NA
NA
NA
Other waste
Nil
Nil
Nil
NA
NA
NA
 
*We have submitted the Extended Producer Responsibility (EPR) registration for CPCB and are currently awaiting approval from 
the Central Pollution Control Board (CPCB). Upon approval, we will receive annual recycling targets from CPCB, commencing next 
year, and will ensure compliance by reporting in accordance with the prescribed regulatory norms.
5. 
Reclaimed products and their packaging materials (as percentage of products sold) for each product category.
Indicate product 
category
Reclaimed products and their packaging materials as % of  
total products sold in respective category
Nil
Principle 3: Business should respect and promote the well-being of all employees, including those in their 
value chains
Essential Indicators
1. 
a.  
Details of measures for the well-being of employees:
Category
% of employees covered by
Total 
(A)
Health  
insurance
Accident 
insurance
Maternity 
benefits
Paternity 
Benefits
Day Care 
facilities
Number 
(B)
%  
(B/A)
Number 
(C)
%  
(C/A)
Number 
(D)
%  
(D/A)
Number 
(E)
%  
(E/A)
Number 
(F)
%  
(F/A)
Permanent employees
Male
401
401
100%
401
100%
_
_
401
100%
401
100%
Female
92
92
100%
92
100%
92
100%
_
_
92
100%
Total
493
493
100%
493
100%
92
19%
401
81%
493
100%
Other than Permanent employees
Male
Nil
Female
Total
 
b. 
Details of measures for the well-being of workers:
Category
% of workers covered by
Total 
(A)
Health  
insurance
Accident 
insurance
Maternity 
benefits
Paternity 
Benefits
Day Care 
facilities
Number 
(B)
% 
(B/A)
Number 
(C)
% 
(C/A)
Number 
(D)
% 
(D/A)
Number 
(E)
% 
(E/A)
Number 
(F)
% 
(F/A)
Permanent workers
Male
87
87
100%
87
100%
_
_
87
100%
87
100%
Female
3
3
100%
3
100%
3
100%
_
_
3
100%
Total
90
90
100%
90
100%
3
3%
87
97%
90
100%
Other than Permanent workers
Male
Nil
Female
Total
12
Sanofi Consumer Healthcare India Limited
2. 
Details of retirement benefits, for Current CY and Previous Financial Year
Benefits
CY 2024
CY 2023
No. of 
employees 
covered as 
a % of total 
employees
No. of 
workers 
covered as 
a % of total 
workers
Deducted and 
deposited 
with the 
authority 
(Y/N/N.A.)
No. of 
employees 
covered as 
a % of total 
employees
No. of 
workers 
covered as 
a % of total 
workers
Deducted and 
deposited 
with the 
authority 
(Y/N/N.A.)
PF
100%
100%
Y
Not Applicable*
Gratuity
100%
100%
Y
ESI
NA
NA
NA
Others – please 
specify
_
_
_
_
_
_
 
* For the year 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 
2023 and demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, 
therefore, covers the period from June 1, 2024, to December 31, 2024.
3. 
Accessibility of workplaces
Are the premises/offices of the entity accessible to differently abled employees and workers, as per the 
requirements of the Rights of Persons with Disabilities Act, 2016? If not, whether any steps are being taken by 
the entity in this regard.
The Company’s premises and offices are designed to be accessible to differently abled employees and workers, in 
compliance with the requirements of the Rights of Persons with Disabilities Act. Key accessibility features include 
dedicated parking, security support, accessible washrooms, adequate space for wheelchair movement, visual and 
audio alarms, emergency evacuation chairs, ramps at entry points in the basement, tactile flooring for visually 
impaired and indicative signage with Braille support.
4. 
Does the entity have an equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016? If so, 
provide a web-link to the policy.
Yes; the Company has a formal equal opportunity policy in place. Sanofi Consumer Healthcare India Limited recognizes 
the importance of fostering a diverse and inclusive workplace that ensures equal opportunities for all. Committed to 
strengthening its governance framework, the Company continuously evaluates and implements policies that uphold 
fairness, inclusivity, and non-discrimination.
5. 
Return to work and Retention rates of permanent employees and workers that took parental leave.
Gender
Permanent employees
Permanent workers
Return to work rate
Retention rate*
Return to work rate
Retention rate*
Male
100%
NA
NA
NA
Female
100%
NA
NA
NA
Total
100%
NA
NA
NA
 
* The Company became an independent entity on June 1, 2024, following its incorporation in 2023 and subsequent demerger 
from Sanofi India Limited through a Scheme of Arrangement. Accordingly, the Business Responsibility & Sustainability Report 
covers the period from June 1, 2024, to December 31, 2024. As a result, the retention rate cannot be determined for this period.
Annual Report 2024
13
6. 
Is there a mechanism available to receive and redress grievances for the following categories of employees and 
workers? If yes, give details of the mechanism in brief.
Yes/No (If yes, then give details of the mechanism in brief)
Permanent Workers
Yes; a Management-Worker Committee Meeting is planned to address 
concerns holistically. Additionally, real-time engagement is maintained through 
continuous interactions with the workers’ representative body, ensuring open 
communication, collaboration, and the fast resolution of issues requiring 
immediate attention.
Other than Permanent Workers
Yes;
Permanent Employees
Sanofi Consumer Healthcare India Limited facilitates open communication 
through forums such as CHC Challenger Connect for all employees and 
Monthly Cycle Meets, Town Halls, and Leadership Connect. Monthly 
Challenger Connect sessions are conducted across multiple locations, 
providing employees with avenues to share their concerns and engage with 
the leadership.
Other than Permanent Employees
Yes
7. 
Membership of employees and workers in association(s) or Unions recognised by the listed entity:
Category
CY 2024
CY 2023*
Total 
employees/
workers in 
respective 
category (A)
No. of employees/
workers in 
respective 
category, who 
are part of 
association(s) or 
Union (B)
% (B/A)
Total 
employees/
workers in 
respective 
category (C)
No. of 
employees/
workers in 
respective 
category, who 
are part of 
association(s) or 
Union (D)
% (D/C)
Total Permanent 
Employees
Male
401
0
0%
NA
NA
NA
Female
92
0
0%
NA
NA
NA
Total
493
0
0%
NA
NA
NA
Total Permanent 
Worker
Male
87
87
100%
NA
NA
NA
Female
3
3
100%
NA
NA
NA
Total
90
90
100%
NA
NA
NA
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
14
Sanofi Consumer Healthcare India Limited
8. 
Details of training given to employees and workers:
Category
CY 2024
CY 2023*
Total 
(A)
On Health and 
safety measures
On Skill 
upgradation
Total 
(D)
On Health and 
safety measures
On Skill 
upgradation
No. (B)
% (B/A)
No. (C)
% (C/A)
No. (E)
% (E/D)
No. (F)
% (F/D)
Employees
Male
401
401
100%
54
13%
Not Applicable
Female
92
92
100%
2
2%
Total
493
493
100%
56
11%
Workers
Male
87
87
100%
0
0%
Not Applicable
Female
3
3
100%
0
0%
Total
90
90
100%
0
0%
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
9. 
Details of performance and career development reviews of employees and worker:
Category
CY 2024
CY 2023*
Total (A)
No. (B)
% (B/A)
Total (C)
No. (D)
% (D/C)
Employees
Male
401
401
100%
Not Applicable
Female
92
92
100%
Total
493
493
100%
Workers
Male
87
87
100%
Not Applicable
Female
3
3
100%
Total
90
90
100%
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
10. Health and safety management system:
 
a. 
Whether an occupational health and safety management system has been implemented by the entity? 
(Yes/No). If yes, the coverage of such a system?
	
	
Yes; Sanofi Consumer Healthcare India Limited is firmly committed to ensuring a safe and secure working 
environment for employees, contractors, sub-contractors, visitors, and neighbouring communities at our offices. 
To uphold these standards, we proactively implement measures to prevent work-related injuries and illnesses, 
mitigate risks, and drive continuous improvements in safety performance.
 
b. 
What are the processes used to identify work-related hazards and assess risks on a routine and 
non-routine basis by the entity?
	
	
Sanofi Consumer Healthcare India Limited has established comprehensive procedures for identifying workplace 
hazards and assessing risks. This includes tailored strategies, HSE manuals, and standard operating procedures 
(SOPs) to ensure effective risk management. Hazard Identification and Risk assessment (HIRA) is conducted 
regularly to mitigate HSE risks and promote a culture of safety and compliance. Additionally, driving behaviour 
and vehicle audits, as well as the internal My Safety Index audit, are implemented to monitor and strengthen 
safety performance.
Annual Report 2024
15
 
c. 
Whether you have processes for workers to report the work-related hazards and to remove 
themselves from such risks. (Y/N)
	
	
Yes, Sanofi Consumer Healthcare India Limited has established a robust mechanism for employees and workers 
to report work-related hazards and hazardous situations. All incidents, near misses, and hazards are reported 
through the HSE Portal – Incident and Near Miss Reporting, following a defined protocol. To proactively mitigate 
risks, Life-Saving Rules are in place, which all employees must follow, ensuring a consistent, structured, and 
systematic approach to workplace safety.
 
d. 
Do the employees/workers of the entity have access to non-occupational medical and healthcare 
services? (Yes/No)
	
	
Yes, the office is well-equipped for managing non-occupational medical conditions. Further, all employees are 
covered under health insurance, statutory health insurance, or any other relevant benefits as per eligibility for 
non-occupational medical and healthcare services.
11. Details of safety related incidents, in the following format:
Safety Incident/Number
Category
CY 2024
CY 2023*
Lost Time Injury Frequency Rate (LTIFR) (per one 
million-person hours worked)
Employees
3.41
NA
Workers
0
NA
Total recordable work-related injuries
Employees
2
NA
Workers
0
NA
No. of fatalities
Employees
0
NA
Workers
0
NA
High consequence work-related injury or ill-health 
(excluding fatalities)
Employees
0
NA
Workers
0
NA
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
12. Describe the measures taken by the entity to ensure a safe and healthy workplace.
	
At Sanofi Consumer Healthcare India Limited, we are committed to upholding the highest standards of safety, 
health, and environmental sustainability. Our EHS framework is aligned with ISO 45001:2018, OSHA standards, and 
applicable regulatory requirements to ensure a safe and compliant work environment. We conduct periodic driving 
behaviour and vehicle audits and regularly organize training sessions on defensive driving, ergonomics, first aid & 
basic life support, office safety, and emergency response to strengthen safety awareness and preparedness across 
the organization. Incident investigations ensure corrective and preventive measures to prevent recurrence.
	
We foster a strong safety culture through structured education, relevant experience, and continuous training, 
ensuring all personnel are equipped to uphold health and safety standards effectively.
13. Number of Complaints on the following made by employees and workers:
CY 2024
CY 2023*
Filed during 
the year
Pending 
resolution 
at the end of 
year
Remarks
Filed during 
the year
Pending 
resolution 
at the end of 
year
Remarks
Working 
Conditions
0
0
NA
Not Applicable
Health & 
Safety
0
0
NA
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024 following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
16
Sanofi Consumer Healthcare India Limited
14. Assessment for the year:
% of your plants and offices that were assessed (by entity or statutory 
authorities or third parties)
Health and safety practices
100%
Working Conditions
100%
15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on 
significant risks/concerns arising from assessments of health & safety practices and working conditions.
	
At Sanofi Consumer Healthcare India Limited, all safety incidents and near misses are investigated in accordance 
with our HSE management system. Corrective and Preventive Actions (CAPA) are identified and systematically 
implemented to mitigate risks and prevent recurrence. Safety performance is continuously monitored through 
quarterly reviews. Key initiatives include Driving Behaviour & Vehicle Audits, My Safety Index Audits, and Road Safety 
Coaching.
Leadership Indicators
1. 
Does the entity extend any life insurance or any compensatory package in the event of death of (A) Employees 
(Y/N) (B) Workers(Y/N).
	
Yes, Sanofi Consumer Healthcare India Limited extends life insurance coverage or a compensatory package for its 
workforce in the event of an employee’s or worker’s death.
2. 
Provide the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited 
by the value chain partners.
	
Sanofi Consumer Healthcare India Limited upholds the highest standards of regulatory compliance by ensuring that all 
statutory dues are deposited in strict adherence with  applicable laws and regulations. This critical process is subject 
to rigorous oversight through both internal and statutory audits, reinforcing our commitment to accountability and 
transparency.
	
Furthermore, we extend these principles across our value chain, expecting our business partners to adhere to the 
same high standards of ethical conduct, transparency, and regulatory compliance.
3. 
Provide the number of employees/workers having suffered high consequence work-related injury/ill-health/
fatalities (as reported in Q11 of Essential Indicators above), who have been rehabilitated and placed in suitable 
employment or whose family members have been placed in suitable employment:
Total no. of affected  
employees/workers
No. of employees/workers that are rehabilitated 
and placed in suitable employment or whose family 
members have been placed in suitable employment
CY 2024
CY 2023*
CY 2024
CY 2023*
Employees
0
NA
0
NA
Workers
0
NA
0
NA
 
For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
4. 
Does the entity provide transition assistance programs to facilitate continued employability and the 
management of career endings resulting from retirement or termination of employment? (Yes/No)
	
Yes, we provide transition assistance on termination of employment.
5. 
Details on assessment of value chain partners:
% of value chain partners (by value of business done with such 
partners) that were assessed
Health and safety practices
Sanofi prioritizes responsible partnerships and implements a rigorous 
supplier assessment process. This process evaluates key areas such as 
Health, Safety & Environment (HSE), Corporate Social Responsibility 
(CSR), Anti-Bribery Due Diligence (ABDD), cybersecurity, and financial 
stability. A multi-pronged approach is employed, involving direct 
assessments for critical and high-emitting suppliers, and leveraging 
third-party platforms for CSR and HSE. The scope of this assessment 
program demonstrates Sanofi’s commitment to responsible sourcing.
Working Conditions
Annual Report 2024
17
6. 
Provide details of any corrective actions taken or underway to address significant risks/concerns arising from 
assessments of health and safety practices and working conditions of value chain partners.
	
There were no instances of risks or concerns identified regarding health and safety practices or working conditions 
of value chain partners.
Principle 4: Business should respect the interests of and be responsive to all its stakeholders
Essential Indicators
1. 
Describe the processes for identifying key stakeholder groups of the entity. 
	
Sanofi Consumer Healthcare India Limited identifies stakeholders through management interactions, industry 
benchmarking, and external engagement. Our key stakeholders include patients, employees, healthcare professionals, 
investors, customers, trade partners, regulators, communities, suppliers, and NGOs. Each contributes to our strategic 
growth, governance, and commitment to responsible business practices. Through meaningful engagement, we foster 
trust, transparency, and long-term value creation.
2. 
List stakeholder groups identified as key for your entity and the frequency of engagement with each stakeholder 
group.
Stakeholder 
Group
Whether 
identified as 
Vulnerable & 
Marginalized 
Group (Yes/
No)
Channels of communication 
(Email, SMS, Newspaper, 
Pamphlets, Advertisement, 
Community Meetings, Notice 
Board, Website), Other
Frequency of 
engagement 
(Annually/
Half yearly/
Quarterly/others 
– please specify)
Purpose and scope of 
engagement including 
key topics and concerns 
raised during such 
engagement
Patients/Patient 
Advocacy 
Groups
No
-	
Market research surveys
-	
Grievance redressal 
mechanism
-	
Workshops and conferences 
with patient advocacy groups
-	
Patient support/assistance 
programs
Continuous
-	
Insights on 
strengthening R&D 
and improving product 
quality
-	
Responding to queries 
and complaints
Healthcare 
Professionals/
Healthcare 
Organizations/
Medical 
Scientific 
Associations
No
-	
Regular business interactions
-	
Customer satisfaction surveys
- 	 Grievance redressal 
mechanism
-	
Workshops and conferences
- 	 Medical educational programs
-	
Sales personnel touchpoints 
(physical/virtual)
Continuous
-	
 Information in and 
around the product and 
therapy area
-	
Insights on 
strengthening R&D 
and improving product 
quality
-	
Frequent engagement 
and understanding 
HCP and patient needs 
Responding to queries 
and complains
Local 
Communities/
NGOs
Yes
-	
Need assessment surveys
-	
Regular meetings through field 
work
-	
Trainings and workshops
-	
Emails and telephonic 
conversations
-	
CSR programs
- 	 Responding to humanitarian 
crisis
Continuous
-	
Increasing awareness 
and understanding of 
disease 
-	
Providing access to 
affordable healthcare 
-	
CSR Activities
18
Sanofi Consumer Healthcare India Limited
Stakeholder 
Group
Whether 
identified as 
Vulnerable & 
Marginalized 
Group (Yes/
No)
Channels of communication 
(Email, SMS, Newspaper, 
Pamphlets, Advertisement, 
Community Meetings, Notice 
Board, Website), Other
Frequency of 
engagement 
(Annually/
Half yearly/
Quarterly/others 
– please specify)
Purpose and scope of 
engagement including 
key topics and concerns 
raised during such 
engagement
Suppliers/
Vendors/Third 
Party Service 
Providers
No
-	
Emails and meetings
-	
Training workshops and 
seminars
-	
Supplier assessment and 
review
-	
Supplier grievance mechanism
- 	 Business Partner touchpoints
- 	 Capability building 
engagements
Continuous
-	
Supplier development
-	
Promoting local 
suppliers
-	
Supplier assessments
-	
Promoting shared 
growth
Employees and 
Contracted 
Workforce
No
-	
Townhall meeting
-	
Training programs
-	
Employee engagement 	
surveys
-	
Employee engagement 
programs
-	
Performance appraisal reviews
-	
Grievance redressal 
mechanism
-	
Emails and meetings
Continuous
-	
Employee health, safety 
and wellbeing initiatives
-	
Providing E-learning and 
development platforms 
for behavioural and skill 
development
-	
Employee engagement 
and satisfaction
-	
Updates and 
communication on 
policies, processes, 
systems
Shareholder/
Investors 
Community
No
- 	 Annual Report
-	
Annual General Meetings 
(AGM)
-	
One-on-one interactions
-	
Announcement through stock 
exchanges and media releases
-	
Company website
-	
Dedicated email ID for Investor 
grievances
-	
Investor/Analyst meet
-	
Quarterly financial statements
-	
Participation in industry bodies
-	
Quarterly corporate 
governance disclosures
Continuous /
Need basis
-	
Financial performance
-	
Operational 
performance
-	
New product launches
-	
Business Outlook
-	
Sustainability
-	
CSR programs
-	
Corporate Governance
-	
Material disclosures
-	
MoU, partnerships
Trade Partners
No
-	
Emails
-	
Meetings
-	
Newsletters
-	
Governance meetings 
Business partner touchpoints
Periodically /
Need basis
-	
Constant evaluation of 
GTM models
-	
Ensure availability of 
products
-	
Explain emerging 
channels of trade
Government 
Authorities
No
-	
Meetings
-	
Representation through 
industry association
-	
Written communications
Need basis
-	
Explaining the 
recommendations for 
policy, issues pertaining 
to the industry
Annual Report 2024
19
Leadership Indicators
1. 
Provide the processes for consultation between stakeholders and the Board on economic, environmental, and 
social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.
	At Sanofi Consumer Healthcare India Limited, we maintain a structured approach to stakeholder engagement, with
department heads regularly interacting with internal and external stakeholders. Insights from these discussions are
shared with senior management and the Board, ensuring informed decision-making and transparent communication.
The Stakeholders’ Relationship Committee is dedicated to addressing shareholder and investor concerns, upholding
accountability and trust.
	Our quarterly Board meetings evaluate key ESG aspects, including safety, environmental performance, and
governance initiatives. Additionally, the CSR Committee actively engages with local communities, providing updates
to the Board every quarter.
2.
Whether stakeholder consultation is used to support the identification and management of environmental,
and social topics (Yes/No). If so, provide details of instances as to how the inputs received from stakeholders 
on these topics were incorporated into policies and activities of the entity.
	Yes; at Sanofi Consumer Healthcare India Limited we actively engaged with all our key stakeholders to identify and
prioritize the issues that matter plays a crucial role. Through collaborative discussions, we gained valuable insights
that help align our strategies with stakeholder expectations, ensuring a responsible approach to Business.
3. 
Provide details of instances of engagement with, and actions taken to, address the concerns of vulnerable/
marginalized stakeholder groups.
	Since its beginning as an independent entity in June 2024, Sanofi Consumer Healthcare India Limited has been
committed to engaging with and addressing the concerns of vulnerable and marginalized communities.
Principle 5: Businesses should respect and promote human rights
Essential Indicators
1.
Employees and workers who have been provided training on human rights issues and policy(ies) of the entity,
in the following format:
Category
CY 2024
CY 2023*
Total (A)
No. of 
employees/
workers 
covered (B)
% (B/A)
Total (C)
No. of 
employees/
workers 
covered (D)
% (D/C)
Employees
Permanent
100%
Not Applicable
Other than permanent
100%
Total Employees
493
493
100%
Workers
Permanent
87
87
100%
Not Applicable
Other than permanent
3
3
100%
Total Workers
90
90
100%
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore,
covers the period from June 1, 2024, to December 31, 2024
20
Sanofi Consumer Healthcare India Limited
493
493
0
0
2. 
Details of minimum wages paid to employees and workers, in the following format:
Category
CY 2024
CY 2023*
Total 
(A)
Equal to
More than
Total 
(D)
Equal to
More than
No. (B)
% (B/A)
No. (C)
% (C/A)
No. (E)
% (E/D)
No. (F)
% (F/D)
Employees
Permanent
Male
401
0
0%
401
100%
Not Applicable
Female
92
0
0%
92
100%
Other than 
Permanent
Male
0
0
0%
0
0%
Not Applicable
Female
0
0
0%
0
0%
Workers
Permanent
Male
87
0
0%
87
100%
Not Applicable
Female
3
0
0%
3
100%
Other than 
Permanent
Male
0
0
0%
0
0%
Not Applicable
Female
0
0
0%
0
0%
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
3. 
Details of remuneration/salary/wages, in the following format:
 
Median remuneration/wages:
Male
Female
Number
Median remuneration/
salary/wages of 
respective category
Number
Median remuneration/
salary/wages of 
respective category
Board of Directors (BoD)*
-
-
-
-
Key Managerial Personnel (KMP)**
3
2,29,41,329
0
-
Employees other than BoD and KMP
399
8,90,155
91
12,32,000
Workers
87
7,21,972
3
10,04,882
 
*The Independent Directors of the Company are entitled to Sitting Fees and Commission as per the statutory provisions. The 
details of remuneration of Non-Executive Directors are provided in the Corporate Governance Report. Sitting fees is paid based 
on the number of meetings attended by an Independent Director and hence the % increase is not comparable.
 
*Non-Executive Directors who are employees of Sanofi group do not receive any Sitting Fees or Commission.
 
**KMPs include the Executive Directors on the Board of the Company.
4. 
Do you have a focal point (Individual/Committee) responsible for addressing human rights impacts or issues 
caused or contributed to by the business? (Yes/No)
	
Yes, Sanofi Consumer Healthcare India Limited has a policy in place for addressing Human Rights issues. The Company 
is committed to upholding fundamental human rights principles across its operations, ensuring ethical and responsible 
business practices.
Annual Report 2024
21
5. 
Describe the internal mechanisms in place to redress grievances related to human rights issues.
	
Sanofi Consumer Healthcare India Limited conducts human rights assessments in accordance with global guidelines 
and norms. The Internal Control team provides assessment forms, which are completed by the P&C team. These 
completed declaration forms are then submitted to the Internal Control team for global reporting and compliance. 
This process ensures adherence to international standards and reinforces the Company’s commitment to ethical and 
responsible business practices.
6. 
Number of Complaints on the following made by employees and workers:
CY 2024
CY 2023*
Filed during 
the year
Pending 
resolution 
at the end of 
year
Remarks
Filed during 
the year
Pending 
resolution 
at the end of 
year
Remarks
Sexual Harassment
Nil
Nil
NA
Not Applicable
Discrimination at 
workplace
Nil
Nil
NA
Child Labour
Nil
Nil
NA
Forced Labour/
Involuntary Labour
Nil
Nil
NA
Wages
Nil
Nil
NA
Other human rights 
related issues
Nil
Nil
NA
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024 following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
7. 
Mechanisms to prevent adverse consequences to the complaint in discrimination and harassment cases.
	
At Sanofi Consumer Healthcare India Limited, we are committed to maintaining the strict confidentiality of 
complainants’ identities in all grievance-handling processes. Investigations are conducted with the highest level of 
discretion to prevent any unintended disclosures of identities.
8. 
Do human rights requirements form part of your business agreements and contracts? (Yes/No)
	
Yes, Human Rights requirements are part of our business agreements and contracts.
9. 
 Assessment for the year:
% of your offices that were assessed (by entity or statutory 
authorities or third parties) *
Child labour
100%
Forced/involuntary labour
100%
Sexual harassment
100%
Discrimination at workplace
100%
Wages
100%
Others-please specify
Not Applicable
 
*Internal assessment was undertaken for the period beginning from June 2024
10. Provide details of any corrective actions taken or underway to address significant risks/concerning arising from 
the assessments at Question 9 above.
	
Not Applicable.
22
Sanofi Consumer Healthcare India Limited
Leadership Indicators
1. 
Details of a business process being modified/introduced as a result of addressing human rights grievances/
complaints.
	
There were zero instances of grievances since the inception of the Company.
2. 
Details of the scope and coverage of any Human rights due diligence conducted.
	
The scope and coverage of Human Rights Due Diligence are currently assessed through internal mechanisms; 
however, the company envisions conducting third-party due diligence in the coming years.
3. 
Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights 
of Persons with Disabilities Act, 2016?
	
At Sanofi Consumer Healthcare India Limited, we are committed to fostering an inclusive, accessible, and safe 
workplace. Our premises are thoughtfully designed to ensure convenience, mobility, and security for everyone. 
Key accessibility features include dedicated parking spaces, security assistance, wheelchair-accessible washrooms, 
wide and unobstructed pathways, visual and audio alarms, emergency evacuation chairs, ramps at basement entry 
points, and Braille signage in lifts.
4. 
Details on assessment of value chain partners:
% of value chain partners (by value of business done with such partners) that 
were assessed
Child labour
Sanofi prioritizes responsible partnerships and implements a rigorous supplier 
assessment process. This process evaluates key areas such as Health, Safety 
& Environment (HSE), Corporate Social Responsibility (CSR), Anti-Bribery 
Due Diligence (ABDD), cybersecurity, and financial stability. A multi-pronged 
approach is employed, involving direct assessments for critical and high-emitting 
suppliers, and leveraging third-party platforms for CSR and HSE. The scope of this 
assessment program demonstrates Sanofi’s commitment to responsible sourcing.
Forced/involuntary labour
Sexual harassment
Discrimination at workplace
Wages
Others-please specify
5. 
Provide details of any corrective actions taken or underway to address significant risks/concerns arising from 
the assessments at Question 4 above.
Not Applicable
Principle 6: Businesses should respect and make efforts to protect and restore the environment
Essential Indicators
1. 
Details of total energy consumption (in Joules or multiples) and energy intensity, in the following format:
Parameter
Unit
CY 2024
CY 2023*
Total electricity consumption (A)
GJ
3,449.09
NA
Total fuel consumption (B)
GJ
0
NA
Energy consumption through other sources (C)
GJ
0
NA
Total energy consumed from renewable sources (A+B+C)
GJ
3,449.09
NA
Energy intensity per million rupee of turnover (Total energy 
consumption/turnover in rupees)
GJ/
0.47
NA
Energy intensity (optional)- the relevant metric may be 
selected by the entity
_
_
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
 
Note: No assessment/evaluation/assurance has been carried out by an external agency
Annual Report 2024
23
2. 
Does the entity have any sites/facilities identified as designated consumers (DCs) under the Performance, 
Achieve and Trade (PAT) Scheme of the Government of India? (Y/N) If yes, disclose whether targets set under 
the PAT scheme have been achieved. In case targets have not been achieved, provide the remedial action taken, 
if any.
	
Sanofi Consumer Healthcare India Limited has no sites or facilities classified as designated consumers under the 
Perform, Achieve, and Trade (PAT) scheme.
3. 
Provide details of the following disclosures related to water, in the following format:
Parameter
CY 2024
CY 2023*
Water withdrawal by source (in kilolitres)
(i)	 Surface Water
0
NA
(ii)	 Ground Water
0
NA
(iii)	Third Party Water (MCGM)
6,231
NA
(iv)	Seawater/desalinated water
0
NA
(v)	 Others (Rainwater)
568
NA
Total volume of water withdrawal (in kilolitres) (i + ii + iii + iv + v)
6,799
NA
Total volume of water consumption (in kilolitres)
6,799
NA
Water intensity per million rupee of turnover (Total Water consumption/
Revenue from operations)
0.94
NA
Water intensity (optional) – the relevant metric may be selected by the entity
-
-
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
 
Note: No assessment/evaluation/assurance has been carried out by an external agency.
4. 
Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and 
implementation.
	
At Sanofi Consumer Healthcare India Limited, we have implemented sewage treatment plant to efficiently manage 
and treat domestic sewage. The treated water is sustainably reused for toilet flushing and gardening, minimizing 
environmental impact and optimizing resource utilization. Any excess wastewater that exceeds internal requirements 
at our Mumbai office is safely discharged in full compliance with Pollution Control Board regulations, ensuring strict 
adherence to environmental standards.
5. 
Please provide details of air emissions (other than GHG emissions) by the entity, in the following format:
Parameter
Please specify unit
CY 2024
CY 2023*
NOx
MT
0.000817
NA
SOx
MT
0.445411
NA
PM
MT
 0.001164732
NA
Persistent organic compounds (POP)
_
_
Volatile organic compounds (VOC)
_
_
Hazardous air pollutants (HAP)
_
_
Others-please specify
_
_
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
 
Note: No assessment/evaluation/assurance has been carried out by an external agency.
24
Sanofi Consumer Healthcare India Limited
6. 
Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) & its intensity, in the following 
format:
Parameter
Unit
CY 2024
CY 2023*
Total Scope 1 emissions (Break-up of the GHG into CO2, 
CH4, N2O, HFCs, PFCs, SF6, NF3, if available)
Metric tonnes of CO2 
equivalent
5.04
NA
Total Scope 2 emissions (Break-up of the GHG into CO2, 
CH4, N2O, HFCs, PFCs, SF6, NF3, if available)
Metric tonnes of CO2 
equivalent
0
NA
Total Scope 1 and Scope 2 emission intensity per million 
rupee of turnover (Total Scope 1 and Scope 2 GHG 
emissions/Revenue from operations)
0.00070
NA
Total Scope 1 and Scope 2 emission intensity (optional) 
– the relevant metric may be selected by the entity
-
-
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
 
Note: No assessment/evaluation/assurance has been carried out by an external agency.
7. 
Does the entity have any project related to reducing Green House Gas emission? If yes, then provide details.
	
As this marks the company’s first year of operations, efforts are currently underway to identify and initiate the most 
appropriate project aimed at effectively reducing greenhouse gas emissions.
8. 
Provide details related to waste management by the entity, in the following format:
Parameter
CY 2024
CY 2023*
Total Waste generated (in metric tonnes)
Plastic waste (A)
0.30
NA
E-waste (B)
1.37
NA
Biomedical waste (C)
1.74
Construction and demolition waste (D)
0
NA
Battery waste (E)
0
NA
Radioactive waste (F)
0
NA
Other Hazardous waste (Process Waste, ETP sludge Used Oil, etc. (G)
0
NA
Other Non-hazardous waste generated. Please specify, if any.  
(Break-up by composition i.e. by materials relevant to the sector)
Other Non-hazardous waste (Paper & Cardboard + Metal Scrap+ Glass 
Waste + Wood Waste + Miscellaneous Non-Hazardous) (H)
49.15
NA
Total (A+B + C + D + E + F + G + H)
52.56
NA
Waste intensity per million rupee of turnover (Total waste generated/
Revenue from operations)
0.0073
NA
Waste intensity (optional) – the relevant metric may be selected by the 
entity
-
NA
For each category of waste generated, total waste recovered through 
recycling, re-using or other recovery operations (in metric tonnes)
Category of waste
i)	
Recycled
0
NA
ii)	 Re-used
0
NA
iii)	 Other recovery operations
0
NA
Total
0
Annual Report 2024
25
Parameter
CY 2024
CY 2023*
For each category of waste generated, total waste disposed by nature 
of disposal method (in metric tonnes)
Category of waste
i)	
Incineration
0
NA
ii)	 Landfilling
0
NA
iii)	 Other disposal operations
0
NA
Total
0
NA
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024 following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
 
Note: No assessment/evaluation/assurance has been carried out by an external agency
 
*All the waste generated at site are sent to authorized vendors who are responsible for recycling the waste
9. 
Briefly describe the waste management practices adopted in your establishments. Describe the strategy 
adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes 
and the practices adopted to manage such wastes.
	
Sanofi is committed to fostering a cleaner and more sustainable environment through the implementation of a 
robust waste management strategy. Aligned with our dedication to environmental stewardship, we have adopted the 
3R approach—Reduce, Reuse, and Recycle—which has significantly minimized waste generation and promoted 
a culture of circularity across our operations. At our Mumbai office, we are advancing sustainability by embracing 
digitalization to enable paperless transactions and electronic payments. 
10. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife 
sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where 
environmental approvals/clearances are required, please specify details in the following format:
Sr.
No.
Location of operations/
offices
Type of operations
Whether the conditions of environmental approval/
clearance are being complied with? (Y/N) If no, the 
reasons thereof and corrective action taken, if any.
Not Applicable as none of the sites are located/situated in/around ecologically sensitive areas.
11. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, 
in the current financial year:
Name and brief 
details of project
EIA Notification 
No.
Date
Whether conducted by 
independent external 
agency (Yes/No)
Results communicated in 
public domain (Yes/No)
Relevant Web 
link
Sanofi Consumer Healthcare India Limited has not conducted any environmental impact assessments in the 
reporting year.
12. Is the entity compliant with the applicable environmental law/regulations/guidelines in India; such as the Water 
(Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection 
act and rules thereunder (Y/N). If not, provide details of all such non-compliances, in the following format:
Sr. 
No.
Specify the law/regulation/
guidelines which was not 
complied with
Provide details 
of the non- 
compliance
Any fines/penalties/action taken by 
regulatory agencies such as pollution 
control boards or by courts
Corrective 
action taken, 
if any
During the reporting period, there were no instances of non-compliance with applicable laws, regulations, or 
guidelines in India. Additionally, the company holds a valid Consent to Operate, issued by the respective State 
Pollution Control Board (SPCB).
26
Sanofi Consumer Healthcare India Limited
Leadership Indicators
1. 
Provide break-up of the total energy consumed (in Joules or multiples) from renewable and non-renewable 
sources, in the following format:
Parameter
Unit
CY 2024
CY 2023*
From renewable sources
Total electricity consumption (A)
GJ
3,449.09
NA
Total fuel consumption (B)
GJ
0
NA
Energy consumption through other sources (C)
GJ
0
NA
Total energy consumed from renewable sources (A+B+C)
GJ
3,449.09
NA
From non-renewable sources
Total electricity consumption (D)
GJ
0
NA
Total fuel consumption (E)
GJ
67.87
NA
Energy consumption through other sources (F)
GJ
0
NA
Total energy consumed from non-renewable sources (D+E+F)
GJ
67.87
NA
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
 
Note: No assessment/evaluation/assurance has been carried out by an external agency
2. 
Provide the following details related to water discharged:
Parameter
CY 2024
CY 2023*
Water discharge by destination and level of treatment (in kilolitres)
i)	
To surface water
0
NA
	
-	
No treatment
_
_
	
-	
With treatment-please specify level of treatment
_
_
ii)	 To Groundwater
0
NA
	
-	
No treatment
_
_
	
-	
With treatment-please specify level of treatment
_
_
iii)	 To Seawater
0
NA
	
-	
No treatment
_
_
	
-	
With treatment-please specify level of treatment
_
_
iv)	 Sent to third parties
0
NA
	
-	
No treatment
_
_
	
-	
With treatment-please specify level of treatment
_
_
v)	 Others
0
NA
	
-	
No treatment
_
_
	
-	
With treatment-please specify level of treatment
_
_
Total water discharge (in kilolitres)
0
NA
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
 
 Note: No assessment/evaluation/assurance has been carried out by an external agency.
3. 
Water withdrawal, consumption and discharge in areas of water stress (in kilolitres):
 
For each facility/plant located in areas of water stress, provide the following information:
 
i) 
Name of the area
 
ii) 
Nature of operations
 
iii) 
Water withdrawal, consumption and discharge in the following format:
	
At Sanofi Consumer Healthcare India Limited, none of the sites falls under water stress areas.
 
Note: No assessment/evaluation/assurance has been carried out by an external agency.
Annual Report 2024
27
4. 
Please provide details of total Scope 3 emissions & its intensity, in the following format:
Sanofi Consumer Healthcare India Limited is currently not tracking its Scope 3 emissions, however shall start mapping 
the same across its operations in the upcoming years.
5. 
With respect to the ecologically sensitive areas reported at Question 10 of Essential Indicators above, provide 
details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention 
and remediation activities.
Not Applicable as our operations do not operate in any of the ecologically sensitive areas.
6. 
If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve 
resource efficiency, or reduce impact due to emissions/effluent discharge/waste generated, please provide 
details of the same as well as outcome of such initiatives, as per the following format:
Sr. 
No
Initiative 
undertaken
Details of the initiative (Web-link, if any, may be 
provided along-with summary)
Outcome of the initiative
1.
Energy Efficient 
Sensors
Daylight and occupancy sensors are provided in all enclosed 
rooms and on the periphery of the open workstations, Energy 
Star Rated (or equivalent performance) appliances,100% 
LED light fixtures, Enhanced Metering with BMS integration
Energy Savings of up to 12%
2.
Water Saving 
Sensor Taps
Use of Low Flow Fixtures, sensor taps, and efficient 
appliances.
Water savings of 47.32%
3.
Water Saving 
Sensor Taps
Use of recycled water for non-potable uses like flushing
Water savings of 88%
4.
Waste Recycling
Construction and Demolition Waste from the project was 
segregated at site and given to haulers for recycling, sold to 
scrap vendors Operational measure for Waste Segregation 
- bins with wet, dry and reject waste plus e waste bins 
provided to meet the demand
Ensuring more than 90% of 
the waste is diverted from the 
landfill
5.
Awareness 
Programme
Educational awareness via signages to reduce resource 
consumption
Reduction in resource 
consumption
7. 
Does the entity have a business continuity and disaster management plan? Give details in 100 words/web link.
Sanofi Consumer Healthcare India Limited has a well-defined Business Continuity and Disaster Recovery Plan to 
ensure operational resilience during emergencies. The plan enables swift response and recovery from disruptions 
arising due to natural calamities, man-made incidents, or unforeseen events. It is periodically reviewed and updated, 
incorporating lessons from past disruptions such as cyclones, floods, and pandemics. Aligned with the Company’s 
risk management framework, it focuses on assessing potential threats and implementing mitigation strategies to 
minimise impact and ensure business continuity.
8. 
Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What 
mitigation or adaptation measures have been taken by the entity in this regard.
Sanofi Consumer Healthcare India Limited conducts due diligence to identify and mitigate risks across our supply 
chain, ensuring operational resilience and business continuity. During the reporting period, we did not identify any 
significant risks or concerns related to human rights, environmental impact, or health and safety across the value 
chain.
9. 
Percentage of value chain partners (by value of business done with such partners) that were assessed for 
environmental impacts.
Nil; However, we shall look forward to assessing our suppliers on environmental parameters in upcoming years.
28
Sanofi Consumer Healthcare India Limited
Principle 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a 
manner that is responsible and transparent
Essential Indicators
1. 
a. 
Number of affiliations with trade and industry chambers/associations.
	
We have four affiliations with trade and industry chambers/associations.
 
b. 
List the top 10 trade and industry chambers/associations (determined based on the total members of such 
a body) the entity is a member of/affiliated to.
Sr.
No.
Name of the trade and industry  
chambers/associations
Reach of trade and industry chambers/
associations (State/National)
1
Federation of Indian Chambers of Commerce and 
Industry (FICCI)
National
2
Organization of Pharmaceutical Producers of India (OPPI)
National
3
Indo French Chamber of Commerce and Industry (IFCCI)
National
4
Advertising Standards Council of India (ASCI)
National
2. 
Provide details of corrective action taken or underway on any issues related to anti-competitive conduct by 
the entity, based on adverse orders from regulatory authorities.
Name of authority
Brief of the case
Corrective action taken
Not Applicable as no cases of anti-competitive conduct were identified during the reporting period.
Leadership Indicators
1. 
Details of public policy positions advocated by the entity:
Sr. 
No.
Public policy advocated
Method resorted for such 
advocacy
Whether 
information 
available 
in public 
domain?  
(Yes/No)
Frequency of 
Review by Board 
(Annually/
Half yearly/
Quarterly/
Others – please 
specify)
Web Link, 
if available
1.
Sanofi Consumer Healthcare 
India 
Limited 
actively 
collaborates with trade and 
industry 
associations 
to 
engage with the government 
and regulators on key industry 
matters. 
Committed 
to 
responsible and transparent 
policy advocacy, the Company 
ensures that its efforts align 
with national interests while 
fostering a conducive regulatory 
environment for sustainable 
growth.
We are actively engaged with 
key industry and business 
associations, 
ensuring 
strong representation and 
meaningful contributions. 
Through proactive policy 
advocacy, 
we 
address 
critical sectoral issues, 
driving positive impact 
and fostering growth for all 
stakeholders.
No
Not Applicable
Not 
Applicable
Annual Report 2024
29
Principle 8: Businesses should promote inclusive growth and equitable development
Essential Indicators
1. 
Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the 
current financial year
Name and 
brief details 
of project
SIA 
Notification 
No.
Date of 
notification
Whether conducted by 
independent external 
agency (Yes/No)
Results 
communicated 
in public domain 
(Yes/No)
Relevant Web link
Not Applicable
2. 
Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken 
by your entity, in the following format:
Sr. 
No
Name of Project for 
which R&R is ongoing State
District No. of Project Affected 
Families (PAFs)
% of PAFs 
covered by R&R
Amounts paid to PAFs 
in the CY (In `)
Not Applicable
3. 
Describe the mechanisms to receive and redress grievances of the community.
Sanofi Consumer Healthcare India Limited is committed to fostering strong community engagement and ensuring 
effective grievance redressal. We have established a dedicated correspondence channel, where our Corporate Social 
Responsibility team actively manages incoming inquiries.
4. 
Percentage of input material (inputs to total inputs by value) sourced from suppliers:
CY 2024*
CY 2023*
Directly sourced from MSMEs/small producers
*
NA
Directly from within India
*
NA
*Segregated data for the calendar years 2023 and 2024 is unavailable, as the entity commenced independent 
operations on June 1, 2024, following its incorporation in 2023 and subsequent demerger from Sanofi India Limited 
through a Scheme of Arrangement. As a result, the Business Responsibility and Sustainability Report pertains solely 
to the period from June 1, 2024, to December 31, 2024. However, due to the transitional nature of this period, 
comprehensive data for this timeframe is currently not traceable.
Leadership Indicators
1. 
Provide details of actions taken to mitigate any negative social impacts identified in the Social Impact 
Assessments (Reference: Question 1 of Essential Indicators above):
Details of negative social impact identified
Corrective action taken
Not Applicable as no negative impacts identified
2. 
Provide the following information on CSR projects undertaken by your entity in designated aspirational districts 
as identified by government bodies:
Sr. 
No.
State
Aspirational District
Amount spent (In `)
Nil
3. 
a. 
Do you have a preferential procurement policy where you give preference to purchase from suppliers 
comprising marginalized/vulnerable groups? (Yes/No)
	
	
No
 
b. 
From which marginalized/vulnerable groups do you procure?
	
	
Not Applicable
 
c. 
What percentage of total procurement (by value) does it constitute?
	
	
Not Applicable
30
Sanofi Consumer Healthcare India Limited
4. 
Details of the benefits derived and shared from the intellectual properties owned or acquired by your entity 
(in the current financial year), based on traditional knowledge:
Sr. 
No.
Intellectual Property based on 
traditional knowledge
Owned/Acquired 
(Yes/No)
Benefit shared 
(Yes/No
Basis of calculating 
benefit share
Nil
5. 
Details of corrective actions taken or underway, based on any adverse order in intellectual property related 
disputes wherein usage of traditional knowledge is involved.
Name of authority
Brief of the Case
Corrective action taken
Nil
6. 
Details of beneficiaries of CSR Projects:
Sr. 
No
CSR Project
No. of persons 
benefitted from 
CSR Projects
% of beneficiaries 
from vulnerable and 
marginalized groups
1.
Project Amrit (A collaborative initiative between Sanofi 
Consumer and Naandi, dedicated to establishing water centers 
across various locations. These centers are providing safe, 
affordable drinking water to underserved local communities, 
accessible 24/7.)
4,742
The Company does not 
track the percentage 
of beneficiaries 
from vulnerable and 
marginalized groups
Principle 9: Businesses should engage with and provide value to their consumers in a responsible manner
Essential indicators
1. 
Describe the mechanisms in place to receive and respond to consumer complaints and feedback.
	
At Sanofi Consumer Healthcare India Limited, any written, electronic, or verbal communication from a customer 
concerning a product is classified as a Product Technical Complaint (PTC) or a Customer Complaint. Upon receipt, 
each complaint is promptly logged into the internal system within the specified timeframe. All complaints are 
investigated and addressed within the defined resolution timelines.
	
The timely intake and closure of complaints are closely monitored as key performance indicators, ensuring effective 
complaint management while maintaining compliance with regulatory and quality standards. The consumer 
complaints/concerns and feedback can be mailed at ptcindia.chc@sanofi.com
2. 
Turnover of products and/services as a percentage of turnover from all products/service that carry information 
about:
As a percentage to total turnover
Environmental and social parameters relevant to the product
100%
Safe and responsible usage
100%
Recycling and/or safe disposal
100%
3. 
Number of consumer complaints in respect of the following:
CY 2024
CY 2023*
Received 
during the 
year
Pending 
resolution at 
end of year
Remarks
Received 
during 
the year
Pending 
resolution at 
end of year
Remarks
Data privacy
Nil
NA
_
Not Available
Advertising
Nil
NA
_
Cyber-security
Nil
NA
_
Delivery of essential services
Nil
NA
_
Restrictive Trade Practices
Nil
NA
_
Unfair Trade Practices
Nil
NA
_
Other (Product Specific Consumer 
Complaints)
138
Nil
_
 
*For CY 2023, data are not applicable as the entity became independent on June 1, 2024, following its incorporation in 2023 and 
demerger from Sanofi India Limited via a Scheme of Arrangement. The Business Responsibility & Sustainability Report, therefore, 
covers the period from June 1, 2024, to December 31, 2024.
Annual Report 2024
31
4. 
Details of instances of product recalls on account of safety issues:
Number
Reasons for recall
Voluntary recalls
4
Precautionary 
Reason
Forced recalls
Nil
NA
5. 
Does the entity have a framework/policy on cyber security and risks related to data privacy? (Yes/No) If available, 
provide a web-link of the policy.
	
The Internal Auditor conducts multiple annual assessments to ensure operational integrity. In addition to traditional 
audits, we employ penetration tests to fortify our security measures. Any identified deviations and risks are 
precisely documented and promptly addressed to uphold our commitment to excellence and mitigate potential 
vulnerabilities.
	
The organization has implemented an international Privacy Policy regarding data confidentiality for its operations, 
which can be accessed via the provided web link: Privacy & data protection (sanofi.com)
6. 
Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of 
essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; 
penalty/action taken by regulatory authorities on safety of products/services.
	
Not Applicable; as no such instances were recorded during CY 2024.
Leadership Indicators
1. 
Channels/platforms where information on products and services of the entity can be accessed (provide web 
link, if available).
	
For detailed information about our products and services, please visit our official website at www.sanofi.in.
2. 
Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.
	
At Sanofi Consumer Healthcare India Limited, each product is accompanied by an informational insert designed to 
educate consumers on its proper usage. These inserts provide essential details, including composition, benefits, safe 
usage guidelines, and recommended storage conditions. To further enhance accessibility to comprehensive product 
information, QR codes are seamlessly integrated into the packaging, allowing consumers to access detailed resources 
on product safety and optimal usage with ease.
3. 
Mechanisms in place to inform consumers of any risk of disruption/discontinuation of essential services.
	
In adherence to the regulations set forth by the National Pharmaceutical Pricing Authority, we adhere to a transparent 
process regarding the discontinuation of any scheduled formulation. This entails issuing a public notice to relevant 
stakeholders and notifying the Government at least six months in advance of the intended discontinuation date.
4. 
Does the entity display product information on the product over and above what is mandated as per local 
laws? (Yes/No/Not Applicable) If yes, provide details in brief. Did your entity carry out any survey with regard to 
consumer satisfaction relating to the major products/services of the entity, significant locations of operation 
of the entity or the entity as a whole? (Yes/No)
	
Yes, at Sanofi Consumer Healthcare India Limited, we ensure that product information for our entire range complies 
with all applicable local regulations. By prominently displaying clear and concise warnings on product packaging, we 
aim to enhance awareness among healthcare professionals and patients.
5. 
Provide the following information relating to data breaches:
 
a. 
Number of instances of data breaches
	
	
There were zero instances reported on the data breaches for Sanofi Consumer Healthcare India Limited.
 
b. 
Percentage of data breaches involving personally identifiable information of customers
	
	
0%
32
Sanofi Consumer Healthcare India Limited
